For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

REXULTI® (brexpiprazole) Agitation associated with dementia due

Alzheimer's Agitation Seen to Ease with Schizophrenia Drug

FDA OKs First Drug for Agitation in Alzheimer's Dementia

Targets, trials and tribulations in Alzheimer therapeutics

Otsuka and Lundbeck Announce U.S. Food and Drug Administration

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

REXULTI® (brexpiprazole) Agitation associated with dementia due

Lundbeck, Otsuka drug cut agitation in Alzheimer's patients

This Antipsychotic Drug Can Now Be Used to Treat Agitation in

FDA approves first drug meant to ease Alzheimer's-linked agitation

Investigation Questions Drug's Approval for Agitation in AD

Lundbeck carries on Rexulti study after new analysis — MedWatch

FDA Approves First Drug to Treat Dementia-Associated Agitation in

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation